Plain-English translation of NCT06706232 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing —a naturally occurring compound—combined with therapy to help people with bipolar II disorder who are struggling with depression and suicidal thoughts. You would receive up to two doses of the medication (25 mg each) along with structured psychological support that includes mindfulness-based cognitive behavioral therapy and preparation and integration sessions typical of psychedelic treatments. Researchers want to know if this combination is safe, acceptable, and effective for reducing suicidal thoughts and depression in this specific group of patients.
People with bipolar II disorder often struggle with severe depression and suicidal thoughts, and current treatments don't work well enough for everyone. This trial exists because researchers believe this medication, when paired with therapy, might offer new hope for patients who haven't found relief with existing treatments.
You likely qualify if…
You likely don't qualify if…
You would attend multiple study visits over several weeks for assessments, medical exams, and blood work. Five weeks before your first dose, you would begin tapering off certain psychiatric medications under medical supervision. On the administration days, you would receive one dose of the medication in a supportive clinical setting with a therapist present, and you would receive preparation sessions before and integration sessions after each dose to help you process the experience. Throughout the study, you would complete questionnaires to track your mood, suicidal thoughts, and how you're responding to the treatment.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
The University of Texas Health Science Center, Houston
Collaborators
Anne and Don Fizer Foundation
Enrollment target
~10 participants
Started
July 2025
Primary completion
January 2027
Age range
25 Years – 70 Years
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Thomas Meyer, PhD
The University of Texas Health Science Center, Houston
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.